CING News & Events

Cingulate files $200M mixed securities shelf

As of September 30, 2025, Cingulate had approximately $6.1 million in cash and cash equivalents, a $6.1 million decrease from December 31, 2024. The Company expects its cash will satisfy its capital needs into the second quarter of 2026 under the current business plan. To advance the commercialization efforts through the May 31, 2026 PDUFA date for CTx-1301, the Company will need to raise approximately $7.0 million of additional capital. As of September 30, 2025, Cingulate had approximately $1.6 million in working capital, a decrease of $6.1 million as compared to $7.7 million as of December 31, 2024.

Cingulate announced the appointment of Bryan Downey as Chief Commercial Officer, CCO, following the U.S. Food and Drug Administration's, FDA, acceptance of Cingulate's New Drug Application, NDA, for CTx-1301 and assignment of a Prescription Drug User Fee Act, PDUFA, target action date of May 31, 2026. Cingulate also announced it has completed a $6 million financing transaction, further strengthening its balance sheet and extending its cash runway into the second quarter of 2026, as the company prepares for commercialization, subject to FDA approval.